Chemotherapeutic management of malignant pleural effusion

Expert Opinion on Pharmacotherapy

Volumn 5, Issue 6, 2004, Pages 1233-1242

  Weatherhead, Mark ^b   Antunes, George ^a  

^a JAMES COOK UNIVERSITY HOSPITAL   (United Kingdom)

^b FREEMAN HOSPITAL   (United Kingdom)

Author keywords

Bleomycin; Doxycycline; Pleural effusion; Pleurodesis; Sclerosant; Talc; Tetracycline; TGF 2

Indexed keywords

ALPHA INTERFERON; ANXIOLYTIC AGENT; BATIMASTAT; BETA INTERFERON; BLEOMYCIN; CHLORMETHINE; CISPLATIN; CORTICOSTEROID; CORYNEBACTERIUM PARVUM EXTRACT; CYTOSINE; DOXORUBICIN; DOXYCYCLINE; ETOPOSIDE; FLUOROURACIL; IMMUNOMODULATING AGENT; INTERLEUKIN 12; LIDOCAINE; MEPACRINE; METALLOPROTEINASE INHIBITOR; MINOCYCLINE; MITOMYCIN; MITOXANTRONE; POVIDONE IODINE; SCLEROSING AGENT; SILVER NITRATE; STREPTOKINASE; TALC; TETRACYCLINE; TRANSFORMING GROWTH FACTOR BETA2; UNINDEXED DRUG;

ADULT RESPIRATORY DISTRESS SYNDROME; DRUG ABSORPTION; FEVER; FLU LIKE SYNDROME; HUMAN; KIDNEY DYSFUNCTION; MENTAL DISEASE; NAUSEA; NEUROLOGIC DISEASE; NEUTROPENIA; NONHUMAN; PATHOPHYSIOLOGY; PLEURA EFFUSION; PLEURA FLUID; PLEURODESIS; REVIEW; SIDE EFFECT; THORAX PAIN;

ADJUVANTS, IMMUNOLOGIC; ADRENAL CORTEX HORMONES; ANIMALS; FIBRINOLYTIC AGENTS; HUMANS; MATRIX METALLOPROTEINASES; PLEURAL EFFUSION, MALIGNANT; PLEURODESIS; SCLEROSING SOLUTIONS; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA2;

EID: 3042734541     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.5.6.1233     Document Type: Review

References (97)

1. MONTE SA, EHYA H, LANG WR: Positive effusion cytology as the initial presentation of malignancy. Acta Cytol. (1987) 31:448-452.
2. LUCALLAN EC, CARR DT: Pleural effusion: a statistical study of 436 patients. N. Engl. J. Med (1955) 252:79-83.
3. SANCHEZ-ARMENGOL A, RODRIGUEZ-PANADERO F: Survival and talc pleurodesis in metastatic carcinoma, revisited. A report of 125 cases. Chest (1993) 104:1482-1485.
4. VAN DE MOLENGRAFT FJJM, VOOIJS GP: Survival of patients with malignancy-associated effusions. Acta Cytol. (1989) 33:911-916.
5. HEFFNER JE, NIETERT PJ, BARBIERI C: Pleural fluid pH as a predictor of survival for patients with malignant pleural effusions. Chest (2000) 117:79-86.
6. ANTONY VB: Immunological mechanisms in pleural disease. Eur. Respir. J. (2003) 21:539-544.
7. MULLER KM: Principles of anatomy and pathology of the pleura. In: The European Respiratory Monograph: Pleural diseases. Loddenkemper R, Antony VB (Eds), European Respiratory Society Journals Ltd, (2002) 22:1-27.
8. CHERNOW B, SAHN SA: Carcinomatous involvement of the pleura: an analysis of 96 patients. Am. J. Med. (1977) 63:695-702.
9. MEYER PC: Metastatic carcinoma of the pleura. Thorax (1966) 21:437-443.
10. KRAFT A, WEINDEL K, OCHS A et al.: Vascular endothelial growth factor in the sera and effusions of patients with malignant and nonmalignant disease. Cancer (1999) 85:178-187.
11. THICKETT DR, ARMSTRONG L, MILLAR AB: Vascular endothelial growth factor (VEGF) in inflammatory and malignant pleural effusions. Thorax (1999) 54:707-710.
12. ZEBROWSKI BK, YANO S, LIU W et al.: Vascular endothelial growth factor levels and induction of permeability in malignant pleural effusions. Clin. Cancer Res. (1999) 5:3364-3368.
13. YANO S, SHINOHARA H, HERBST RS et al.: Production of experimental malignant pleural effusion is dependent on invasion of the pleura and expression of vascular endothelial growth factor/vascular permeability factor by human lung cancer cells. Am. J. Pathol. (2000) 157:1893-1903.
14. PATZ EF: Malignant pleural effusions. recent advances and ambulatory sclerotherapy. Chest (1998) 113:74S-77S.
15. PARULEKAR W, DI PRIMIO G, MATZINGER F, DENNIE C, BOCIEK G: Use of small-bore versus large bore chest tubes for treatment of malignant pleural effusions. Chest (2001) 120:19-25.
16. VILLANUEVA AG, GRAY AW Jr, SHAHIAN DM, WILLIAMSON WA, BEAMIS JF: Efficacy of short term versus long term tube thoracostomy drainage before tetracycline pleurodesis in the treatment of malignant pleural effusions. Thorax (1994) 49:23-25.
17. ANTONY VB: Pathogenesis of malignant pleural effusions and talc pleurodesis. Pneumologie (1999) 53:493-498.
18. SPEIGLER PA, HUREWITZ AN, GROTH ML: Rapid pleurodesis for malignant pleural effusions. Chest (2003) 123:1895-1898.
19. LORCH DG, GORDON L, WOOTEN S, COOPER JF, STRANGE C, SAHN SA: Effect of patient positioning on distribution of tetracycline in the pleural space during pleurodesis. Chest (1988) 93:527-529.
20. DRYZER SR, ALLEN ML, STRANGE C, SAHN SA: A comparison of rotation and nonrotation in tetracycline pleurodesis. Chest (1993) 104:1763-1766.
21. MAGER HJ, MAESEN B, VERZIJLBERGEN F, SCHRAMEL F: Distribution of talc suspension during treatment of malignant pleural effusion with talc pleurodesis. Lung Cancer (2002) 36:77-81.
22. AMERICAN THORACIC SOCIETY: Management of malignant pleural effusions. Am. J. Respir. Crit. Care Med. (2000) 162:1987-2001.
23. ANTUNES G, NEVILLE E, DUFFY J, ALI N: BTS guidelines for the management of malignant pleural effusions. Thorax (2003) 58(Suppl. 2):29-38.
24. MC ALPINE LG, HULKS G, THOMPSON NC: Management of recurrent malignant pleural effusion in the United Kingdom: survey of clinical practice. Thorax (1990) 45:699-701.
25. STRANGE C, TOMLINSON JR, WILSON C, HARLEY R, MILLER KS, SAHN SA. The histology of experimental pleural injury with tetracycline, empyema and carrageenan. Exp. Mol. Pathol. (1989) 51:205-219.
26. KROEGEL C, ANTONY VB: Immunobiology of pleural inflammation: potential implications for pathogenesis, diagnosis and therapy. Eur. Respir. J. (1997) 10:2411-2418.
27. ANTONY VB, ROTHFUSS KJ, GODBEY SW, SPARKS JA, HOTT JW: Mechanism of tetracycline-hydrochloride induced pleurodesis. Am Rev Respir Dis. (1992) 146:1009-1013.
28. ZALOZNIK AJ, OSWOLD SG, LANGIN M: Intrapleural tetracycline in malignant pleural effusions. Cancer (1983) 51:752-755.
29. EMAD A, REZAIAN GR: Treatment of malignant pleural effusions with a combination of bleomycin and tetracycline. A comparison of bleomycin or tetracycline alone versus a combination of bleomycin and tetracycline. Cancer (1996) 78:2498-2501.
30. MARTINEZ-MORAGON E, APARICIO J, ROGADO MC, SANCHIS J, SANCHIS F, GIL-SUAY V: Pleurodesis in malignant pleural effusions: a randomised study of tetracycline versus bleomycin. Eur. Respir. J. (1997) 10:2380-2383.
31. SHERMAN S, GRADY KJ, SEIDMAN JC: Clinical experience with tetracycline pleurodesis of malignant pleural effusions. South Med. J. (1987) 80:716-719.
32. WALKER-RENARD PB, VAUGHAN LM, SAHN SA: Chemical pleurodesis for malignant pleural effusions. Ann. Intern. Med. (1994) 120:56-64.
33. HEFFNER JE, STANDERFER RJ, TORSTVEIT J, UNRUH L: Clinical efficacy of doxycycline for pleurodesis. Chest (1994) 105:1743-1747.
34. PATZ EF, MCADAMS HP, ERASMUS JJ et al.: Sclerotherapy for malignant pleural effusions. A prospective randomised trial of bleomycin versus doxycycline with small-bore catheter drainage. Chest (1998) 113:1305-1311.
35. KITAMURA S, SUGIYAMA Y, IZUMI T, HAYSDH R, KOSAKA K: Intrapleural doxycycline for control of malignant pleural effusion. Curr. Ther. Res. (1981) 30:515-521.
36. HATTA T, TSUBUOTA N, YOSHIMURA M, YANAGAWA M: Intrapleural minocycline for postoperative air leakage and control of malignant pleural effusion. Kyobu Geka. (1990) 43:283-286.
37. LIGHT RW, WANG NS, SASOON CS, GRUER SE, VARGAS FS: Comparison of the effectiveness of tetracycline and minocycline as sclerosing agents in rabbits. Chest (1994) 106:577-582.
38. SASSOON CS, LIGHT RW, VARGAS FS, GRUER SE, WANG N: Temporal Evolution of pleural fibrosis induced by intrapleural minocycline injection. Am. J. Respir. Crit. Care Med. (1994) 151:791-794.
39. BETHUNE N: Pleural poudrage: a new technique for the deliberate production of pleural adhesions as a preliminary to lobectomy. J. Thorac. Surg. (1935) 4:251-261.
40. KENNEDY L, VAUGHAN LM, STEED LL, SAHN SA: Sterilization of talc for pleurodesis. Available techniques, efficacy and cost analysis. Chest (1995) 107:1032-1034.
41. VAN DEN HEUVEL MM, SMIT HJM, BARBIERATO SB, HAVENITH CEG, BEELEN RHJ, POSTMUS PE: Talc-induced inflammation in the pleural cavity. Eur. Respir. J. (1998) 12:1419-1423.
42. KENNEDY L, HARLEY RA, SAHN SA, STRANGE C: Talc slurry pleurodesis. pleural fluid and histological analysis. Chest (1995) 107:1707-1712.
43. RODRIGUEZ-PANADERO F, SEGADO A, MARTIN JUAN J, AYERBE R, TORRES GARCIA I, CASTILLO J: Failure of talc pleurodesis is associated with increased pleural fibrinolysis. Am. J. Respir. Crit. Care Med. (1995) 151:785-790.
44. CHENG DS, ROGERS J, WHEELER A, PARKER R, TEIXEIRA L, LIGHT RW: The effects of intrapleural polyclonal antitumor necrosis factor alpha (TNF alpha) fab fragments on pleurodesis in rabbits. Lung (2000) 178:19-29.
45. KENNEDY L, SAHN SA. Talc pleurodesis for the treatment of pneumothorax and pleural effusion. Chest (1994) 106:1215-1222.
46. YIM AP, CHAN AT, LEE TW, WAN IY, HO JK: Thorascopic talc insufflation versus talc slurry for symptomatic malignant pleural effusion. Ann. Thorac. Surg. (1996) 62:1655-1658.
47. ZIMMER PW, HILL M, CASEY K, HARVEY E, LOW DE: Prospective randomised trial of talc slurry versus bleomycin in pleurodesis for symptomatic malignant pleural effusions. Chest (1997) 112:430-434.
48. ONG KC, INDUMATHI V, RAGHURAMJ, ONG YY: A comparative study of pleurodesis using talc slurry and bleomycin in the management of malignant pleural effusions. Respirology (1999) 5:99-103.
49. KUZDZAL J, STADEK K, WASOWSKI D et al.: Talc powder versus doxycycline in the control of malignant pleural effusion: a prospective randominzed trial. Med. Sci. Monit. (2003) 9:172-177.
50. RINALDO JE, OWENS GR, ROGERS RM: Adult respiratory distress syndrome following intrapleural instillation of talc. J. Thorac. Cardiovasc. Surg. (1983) 85:523-526.
51. BOUCHAMA A, CHASTRE J, GAUDICHET A, SOLER P, GILBERT C: Acute pneumonitis with bilateral pleural effusion after talc pleurodesis. Chest (1994) 86:795-797.
52. BONDOC AY, BACH P, ELS NV: Talc pneumonitis: incidence, clinical features and outcome. Chest (1999) 116:358S-359S.
53. SAHN S: Talc should be used for pleurodesis. Am. J. Respir. Crit. Care Med. (2000) 162:2023-2024.
54. WEREBE EC, PAZETTI R, MILANEZ DE CAMPOS JR et al.: Systemic distribution of talc after intrapleural administration in rats. Chest (1998) 115:190-193.
55. MONTES JF, FERRER J, VILLARINO MA, BAEZA B, CRESPO M, GARCIA-VALERO J: Influence of talc dose on extrapleural talc dissemination after talc pleurodesis. Am. J. Respir. Crit. Care Med. (2003) 168:348-355.
56. FERRER J, MONTES JF, VILLARINO MA, LIGHT RW, GARCIA-VALERO J: Influence of particle size on extrapleural talc dissemination after talc slurry pleurodesis. Chest (2002) 122:1018-1027.
57. FRATICELLI A, ROBAGLIA-SCHLUPP A, RIERA H, MONJANEL-MOUTERDE S, CAU P, ASTOUL P: Distribution of calibrated talc after intrapleural administration. An experimental study in rats. Chest (2002) 122:1737-1741.
58. ANDREWS C, GORA ML: Pleural effusions: pathophysiology and management. Ann. Pharmacother. (1994) 28:894-902.
59. OSTROWSKI MJ, HALSALL GM: Intracavity bleomycin in the management of malignant effusions: a multicenter study. Cancer Treat Rep. (1982) 66:1903-1907.
60. RUCKDESCHEL J, MOORES D, LEE JY et al.: Intrapleural therapy for malignant pleural effusions. A randomised comparison of bleomycin and tetracycline. Chest (1991) 100:1528-1535.
61. LYNCH TJ, KALISH L, MENTZER S, DECAMP M, STRAUSS G, SUGARBAKER DJ: Optimal therapy of malignant pleural effusions. Report of a randomised trial of bleomycin, tetracycline and talc and a meta analysis. Int. J. Oncol. (1996) 8:183-190.
62. BITRAN JD, BROWN C, DESSER RK, KOZLOFF MF, SHAPIRO C, BILLINGS AA: Intracavity bleomycin for the control of malignant effusions. J. Surg. Oncol. (1981) 16:273-277.
63. OSTROWSKI MJ: Intracavity therapy with bleomycin for the treatment of malignant pleural effusions. J. Surg. Oncol. (1989) 1(Suppl.):7-13.
64. TROTTER JM, STUART JFB, MCBETH F, MC VIE JG, CALMAN KC: The management of malignant effusions with bleomycin. Br. J. Cancer. (1979) 40:310.
65. AUDU PB, SING RF, METTE SA, FALLAHNEJHAD M: Fatal diffuse alveolar injury following use of intrapleural bleomycin. Chest (1993) 103:1638.
66. GROTH G, GATZEMEIER U, HAUBINGEN K et al.: Intrapleural palliative treatment of malignant pleural effusions with mitoxantrone versus placebo (pleural tube alone). Ann. Oncol. (1991) 2:213-215.
67. CHENG D, CHAN YM, NG TY, CHEUBG AN, NGAN HY, WONG LC: Mitomycin chemotherapeutic pleurodesis to palliate malignant pleural effusions secondary to gynecological cancer. Acta Obstet. Gynecol. Scand. (1999) 78:443-446.
68. ROSSO R, RIMOLDI R, SALVATI F et al.: Intrapleural natural beta interferon in the treatment of malignant pleural effusions. Oncology (1988) 45:253-256.
69. GOLDMAN CA, SKINNIDER LF, MAKSYMIUK AW: Interferon instillation for malignant pleural effusions. Ann. Oncol. (1993) 4:141-145.
70. MASOTTI A, FUMAGALLI L, MORANDINI GC: Intrapleural administration of recombinant interleukin-2 in non-small cell lung cancer with a neoplastic pleural effusion. Monaldi Arch. Chest Dis. (1997) 52:225-228.
71. VIALLAT JR, BOUTIN C, REY F, ASTOUL P, FARISSE P, BRANDELY M: Intrapleural immunotherapy with escalating doses of interleukin -2 in non small cell lung cancer with metastatic pleural effusions. Cancer (1993) 71:4067-4071.
72. MEJER J, MORTENSEN KM, HANSEN H: Mepacrine hydrochloride in the treatment of malignant pleural effusion. Scand. J. Resp. Dis. (1977) 58:319-323.
73. BAYLY T, KISNER D, SYBERT A, MACDONALD JS, TSOU E, SCHEIN PS: Tetracycline and quinacrine in the control of malignant pleural effusions. Cancer (1978) 41:1188-1192.
74. WEINGART SN, HAMLETT F, MILLER BD: Acute mental state changes following intrapleural instillation of quinacrine for traumatic pneumothorax. Psychosomatics (1996) 37:74-78.
75. BORDA I, KRANT M: Convulsions following intrapleural administration of quinacrine hydrochloride. JAMA (1967) 201:1049-1050.
76. BJORKMAN S, ELISSON LO, GABRIELSSON J: Pharmacokinetics of quinacrine after intrapleural instillation in rabbits and man. J. Pharm. Pharmacol. (1989) 41:160-163.
77. KOLDSLAND S, SVENNEVIG JL, LEHNE G, JOHNSON E: Chemical pleurodesis in malignant pleural effusions: a randomised prospective study of mepacrine versus bleomycin. Thorax (1993) 43:790-793.
78. VARGAS FS, TEIXEIRA LR, VAZ MA et al.: Silver nitrate is superior to talc slurry in producing pleurodesis in rabbits. Chest (2000) 118:808-813.
79. VARGAS FS, TEIXEIRA LR, ANTOLANGELO L et al.: Experimental pleurodesis in rabbits induced by silver nitrate or talc. 1-Year follow-up. Chest (2000) 119:1516-1520.
80. OLIVARES-TORRES C, LANIADO-LABORIN R, CHAVEZ-GARCIA C, LEON-GASTELUM C, REYES-ESCAMILLA A, LIGHT RW: Iodopovidone pleurodesis for recurrent pleural effusions. Chest (2002) 122:581-583.
81. MILLAR JW, HUNTER AM, HORNE NW: Intrapleural immunotherapy with Corynebacterium parvum in recurrent malignant pleural effusions. Thorax (1979) 35:856-858.
82. MCLEOD DT, CALVERLEY PMA, MILLAR JW, HORNE NW: Further experience of Corynebacterium parvum in malignant pleural effusion. Thorax (1985) 40:515-518.
83. HILLERDAL G, KIVILOOG J, NOU E, STEINHOLTZ L: Corynebacterium parvum in malignant pleural effusion. A randomised prospective study. Eur. J. Respir. Dis. (1986) 69:204-206.
84. BILACEROGLU S, CAGIRICI U, PERIM K, OZACAR R: Corynebacterium parvum pleurodesis and survival is not significantly influenced by pleural pH and glucose level. Monaldi Arch. Chest Dis. (1998) 53:14-22.
85. LEAHY BC, HONEYBOURNE D, BREAR SG, CARROLL KB, THATCHER N, STRETTON TB: Treatment of malignant pleural effusions with intrapleural Corynebacterium parvum or tetracycline. Eur. J. Respir. Dis. (1985) 66:50-64.
86. FORESTI V: Intrapleural corynebacterium parvum for recurrent malignant pleural effusions. Respiration (1995) 62:21-26.
87. LEE YCG, TEIXEIRA LR, DEVIN CJ et al.: Transforming growth factor-b2 induces pleurodesis significantly faster than talc. Am. J. Respir. Crit. Care Med. (2001) 163:640-644.
88. LIGHT RW, CHENG DS, LEE YC, ROGERS J, DAVIDSON J, LANE KB: A single intrapleural injection of transforming growth factor-b2 produces an excellent pleurodesis in rabbits. Am. J. Respir. Crit. Care Med. (2000) 162:98-104.
89. LEE YCG, LANE KB, PARKER RE et al.: Transforming growth factor B2 produce effective pleurodesis in sheep with no systemic complications. Thorax (2000) 55:1058-1062.
90. LEE YCG, LANE KB, ZOIA O, THOMPSON PJ, LIGHT RW. BLACKWELL TS: Transforming growth factor-B induces collagen synthesis without inducing IL-8 production in mesothelial cells. Eur. Respir. J. (2003) 22:197-202.
91. MACAULAY VM, O'BYRNE KJ, SAUNDERS MP et al.: Phase I study of intrapleural batimastat (BB-94), a matrix metalloproteinase inhibitor, in the treatment of malignant pleural effusions. Clinical Cancer Res. (1999) 5:513-520.
92. TEIXEIRA LR, WU W, CHANG DS, LIGHT RW: The effect of corticosteroids on pleurodesis induced by doxycycline in rabbits. Chest (2002) 121:216-219.
93. CANMAO X, TEIXEIRA LR, MCGOVERN JP, LIGHT RW: Systemic corticosteroids decrease the effectiveness of talc pleurodesis. Am. J. Respir. Crit. Care Med. (1998) 157:1441-1444.
94. LEE YCG, DEVIN CJ, TEIXEIRA LR et al.: Transforming growth factor B2 induced pleurodesis is not inhibited by corticosteroids. Thorax (2001) 56:643-648.
95. DE GREGORIO MA, RUIZ C, ALFONSO ER, FERNANDEZ JA, MEDRANO J, ARINO I: Transcatheter intracavity fibrinolysis of loculated pleural effusions: experience in 102 patients. Cardiovasc. Intervent. Radiol. (1999) 22:114-118.
96. JERJES-SANCHES C, RAMIREZ-RIVERA A, ELIZALDE JJ et al.: Intrapleural fibrinolysis with streptokinase as an adjunctive treatment in haemothorax and empyema. a multicenter trial. Chest (1996) 109:1514-1519.
97. DAVIES CW, TRAILL ZC, GLEESON FV, DAVIES RJ: Intrapleural streptokinase in the management of malignant multiloculated pleural effusions. Chest (1999) 115:729-733.